JP2015506912A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506912A5
JP2015506912A5 JP2014543533A JP2014543533A JP2015506912A5 JP 2015506912 A5 JP2015506912 A5 JP 2015506912A5 JP 2014543533 A JP2014543533 A JP 2014543533A JP 2014543533 A JP2014543533 A JP 2014543533A JP 2015506912 A5 JP2015506912 A5 JP 2015506912A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506912A (ja
JP6180425B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066038 external-priority patent/WO2013078191A1/en
Publication of JP2015506912A publication Critical patent/JP2015506912A/ja
Publication of JP2015506912A5 publication Critical patent/JP2015506912A5/ja
Application granted granted Critical
Publication of JP6180425B2 publication Critical patent/JP6180425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543533A 2011-11-23 2012-11-20 Her3に特異的な結合分子及びそれらの使用 Active JP6180425B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161563092P 2011-11-23 2011-11-23
US61/563,092 2011-11-23
US201261656670P 2012-06-07 2012-06-07
US61/656,670 2012-06-07
US201261722558P 2012-11-05 2012-11-05
US61/722,558 2012-11-05
PCT/US2012/066038 WO2013078191A1 (en) 2011-11-23 2012-11-20 Binding molecules specific for her3 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017047055A Division JP6513728B2 (ja) 2011-11-23 2017-03-13 Her3に特異的な結合分子及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2015506912A JP2015506912A (ja) 2015-03-05
JP2015506912A5 true JP2015506912A5 (cg-RX-API-DMAC7.html) 2016-01-21
JP6180425B2 JP6180425B2 (ja) 2017-08-23

Family

ID=48470246

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543533A Active JP6180425B2 (ja) 2011-11-23 2012-11-20 Her3に特異的な結合分子及びそれらの使用
JP2017047055A Active JP6513728B2 (ja) 2011-11-23 2017-03-13 Her3に特異的な結合分子及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017047055A Active JP6513728B2 (ja) 2011-11-23 2017-03-13 Her3に特異的な結合分子及びそれらの使用

Country Status (17)

Country Link
US (3) US9220775B2 (cg-RX-API-DMAC7.html)
EP (2) EP2797957B1 (cg-RX-API-DMAC7.html)
JP (2) JP6180425B2 (cg-RX-API-DMAC7.html)
KR (1) KR102080535B1 (cg-RX-API-DMAC7.html)
CN (2) CN104093743B (cg-RX-API-DMAC7.html)
AU (1) AU2012340766B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012539B1 (cg-RX-API-DMAC7.html)
CA (1) CA2856297C (cg-RX-API-DMAC7.html)
CO (1) CO7051008A2 (cg-RX-API-DMAC7.html)
DK (1) DK2797957T3 (cg-RX-API-DMAC7.html)
ES (1) ES2745684T3 (cg-RX-API-DMAC7.html)
IL (1) IL232726B2 (cg-RX-API-DMAC7.html)
MX (1) MX350957B (cg-RX-API-DMAC7.html)
RU (1) RU2620068C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201402536PA (cg-RX-API-DMAC7.html)
WO (1) WO2013078191A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403570B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012539B1 (pt) 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
UY34487A (es) * 2011-12-05 2013-07-31 Novartis Ag Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015048008A2 (en) * 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
FI3805268T3 (fi) 2014-02-28 2025-01-07 Merus Nv Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
DK3125885T3 (da) * 2014-04-04 2021-09-27 Astrazeneca Ab Kombination af egfr-inhibitor og mek-inhibitor til anvendelse til behandling af nras-muteret cancer
WO2015157634A1 (en) * 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US20170190788A1 (en) * 2014-09-11 2017-07-06 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
WO2016168634A1 (en) * 2015-04-17 2016-10-20 Bulldog Pharmaceuticals, Inc. Biomarkers related to treatment of cancer with her3 and egfr inhibitors
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Her3抗體
SI3365373T1 (sl) 2015-10-23 2021-08-31 Merus N.V. Vezne molekule, ki zaviranjo rast raka
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
CA3011949A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
KR101796684B1 (ko) 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
US20200061031A1 (en) * 2017-02-28 2020-02-27 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
CN110724194B (zh) * 2018-07-17 2021-03-19 上海生物制品研究所有限责任公司 抗her3人源化单克隆抗体及其制剂
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN110760003A (zh) * 2019-09-10 2020-02-07 广东药科大学 一种抗her3单链抗体的制备方法
EP4044809A4 (en) * 2019-11-12 2023-11-29 University of Virginia Patent Foundation DESIGN OF AN OPTICAL ENZYME CUTTER FOR AGE-RELATED MACULAR DEGENERATION
CA3253194A1 (en) * 2022-03-03 2025-04-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. HER3-BINDING PROTEIN AND ITS USAGE
CN120077074A (zh) * 2022-10-19 2025-05-30 普众发现医药科技(上海)有限公司 抗体-药物偶联物及其制备方法和在抗肿瘤中的用途

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546806C2 (cg-RX-API-DMAC7.html) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
NZ331360A (en) 1996-03-27 2000-03-27 Genentech Inc an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US5804968A (en) 1997-01-29 1998-09-08 Picker International, Inc. Gradient coils with reduced eddy currents
US20030105057A1 (en) 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
WO1998056808A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
WO2001000245A2 (en) 1999-06-25 2001-01-04 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1133565B1 (en) 1999-07-02 2010-09-22 MorphoSys AG Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN109395082A (zh) 2000-05-19 2019-03-01 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2002087619A1 (en) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US7638302B2 (en) 2001-05-31 2009-12-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
MXPA03011365A (es) 2001-06-13 2005-03-07 Genmab As Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr).
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
WO2003012072A2 (en) 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
UA77765C2 (en) 2002-03-13 2007-01-15 Array Biopharma Inc N3 alkylated derivatives of benzimidazole as mek inhibitors
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
CN101711866A (zh) * 2002-07-15 2010-05-26 健泰科生物技术公司 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004012769A1 (en) 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
US20060067947A1 (en) 2002-09-19 2006-03-30 Orient Cancer Therapy Co., Ltd. Immunotherapeutic for cancer
PT1578446E (pt) 2002-11-07 2015-07-22 Immunogen Inc Anticorpos anti-cd33 e processo para tratamento de leucemia mieloide aguda usando os mesmos
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CA2517074A1 (en) 2003-02-27 2004-09-10 Yeda Research And Development Co., Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン,エルエルシー 組換えil−9抗体およびその使用
TW568408U (en) 2003-05-14 2003-12-21 High Tech Comp Corp Slide structure
EP2389953A1 (en) 2003-06-09 2011-11-30 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CA2531595C (en) 2003-07-28 2015-12-08 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
JP2007510708A (ja) 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的erbB2阻害剤/抗erbB抗体の組合せ
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
US20060034840A1 (en) 2004-04-08 2006-02-16 Agus David B ErbB antagonists for pain therapy
US8124085B2 (en) 2004-05-05 2012-02-28 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
WO2006042002A2 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
ES2440481T3 (es) 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
WO2006096663A2 (en) 2005-03-07 2006-09-14 Targeted Molecular Diagnostics, Llc Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease
WO2006133460A2 (en) 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101309933A (zh) * 2005-09-07 2008-11-19 米迪缪尼有限公司 毒素偶联的Eph受体抗体
WO2007030642A2 (en) * 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP2009532393A (ja) 2006-04-07 2009-09-10 コペンハーゲン ユニバーシティ ErbB受容体由来ペプチド断片
WO2007122369A2 (en) 2006-04-13 2007-11-01 Oncomethylome Sciences Sa Novel tumour suppressor
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
WO2008064884A1 (en) 2006-11-28 2008-06-05 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2008081331A2 (en) 2006-12-29 2008-07-10 Sinomab Bioscience Limited Enhancing the level of antibody expression by framework re-engineering
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US20090258005A1 (en) 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US20110189203A1 (en) * 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
ES2433840T3 (es) 2008-04-09 2013-12-12 Universidad De Barcelona Anticuerpos para el tratamiento del cáncer
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2009157919A1 (en) 2008-06-23 2009-12-30 Tumor Biology Investment Group, Inc. SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
EP2159836B1 (en) 2008-08-25 2017-05-31 Soitec Stiffening layers for the relaxation of strained layers
BRPI0921407A2 (pt) 2008-11-07 2019-09-24 Enzo Pharmaceuticals Inc terapia de combinação seletiva de erbb-3 (her3)
EP2358734A1 (en) 2008-12-16 2011-08-24 Millipore Corporation Purification of proteins
CA2753119A1 (en) 2009-02-24 2010-09-02 F. Hoffmann-La Roche Ag Use of s-erbb-3 as a marker for cancer
CA2755640C (en) 2009-03-20 2018-05-22 Genentech, Inc. Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
EP2448599A1 (en) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
AU2010303443A1 (en) * 2009-10-09 2012-04-19 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-Her 3 antibodies
EP2488199A1 (en) 2009-10-14 2012-08-22 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
PL2719708T3 (pl) 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
ES2571226T3 (es) * 2009-12-22 2016-05-24 Roche Glycart Ag Anticuerpos anti-HER3 y usos de los mismos
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
AU2011245636B2 (en) * 2010-04-09 2016-12-22 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
WO2011153383A1 (en) 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9346889B2 (en) 2010-10-18 2016-05-24 Mediapharma S.R.L. ErbB3 binding antibody
EP2635605B1 (en) 2010-11-01 2018-07-25 Symphogen A/S Anti-her3 antibodies and compositions
JP2014509593A (ja) 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ErbB経路阻害剤に対する耐性の克服
KR20140033152A (ko) 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 항erbB3 항체
IN2014CN03042A (cg-RX-API-DMAC7.html) 2011-09-30 2015-07-03 Regeneron Pharma
WO2013071058A1 (en) 2011-11-09 2013-05-16 The Uab Research Foundation Her3 antibodies and uses thereof
BR112014012539B1 (pt) 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
UY34487A (es) 2011-12-05 2013-07-31 Novartis Ag Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
ES2868174T3 (es) 2012-03-29 2021-10-21 Translate Bio Ma Inc Lípidos catiónicos ionizables
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2015048008A2 (en) * 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US20170190788A1 (en) 2014-09-11 2017-07-06 Bulldog Pharmaceuticals, Inc. Uses of anti-her3 antibodies for treating cancer
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
JP2015506912A5 (cg-RX-API-DMAC7.html)
JP2017149720A5 (cg-RX-API-DMAC7.html)
RU2014120757A (ru) Связывающие молекулы, специфичные по отношению к her3, и их применения
CN106519034B (zh) 抗pd-1抗体及其用途
CN111182919B (zh) 抗cd137抗体
KR102078292B1 (ko) 신규한 항 c-Met 항체 및 이의 용도
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2019519492A5 (cg-RX-API-DMAC7.html)
RU2017105915A (ru) Антитела против pd-1
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
JP2018503365A5 (cg-RX-API-DMAC7.html)
JP2016526904A5 (cg-RX-API-DMAC7.html)
JP2014530017A5 (cg-RX-API-DMAC7.html)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2015529641A5 (cg-RX-API-DMAC7.html)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP7328324B2 (ja) Tim-3に対する抗体およびその使用
US20230331867A1 (en) Nectin-4 antibodies and uses thereof
US20240383978A1 (en) Bispecific binding proteins that bind cd137 and a tumor associated antigen
JP2013512278A5 (cg-RX-API-DMAC7.html)
TW202241944A (zh) 新穎的抗gremlin1抗體
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
US20250064909A1 (en) Anti-tigit antibodies and use thereof
CN113893341B (zh) 抗体
CA3154649A1 (en) Anti-stem cell factor antibodies and methods of use thereof in renal disease